BioMarin 8-K: Executive Compensation Arrangements Updated
Ticker: BMRN · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-compensation, corporate-governance, 8-K, management-change
TL;DR
**BioMarin updated executive pay arrangements, watch for strategic shifts.**
AI Summary
BioMarin Pharmaceutical Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 5, 2024, related to changes in its executive compensation arrangements. This filing, under Item 5.02, signals potential shifts in how the company incentivizes its leadership, which could impact future financial performance and investor confidence. For shareholders, understanding these changes is crucial as executive compensation can influence management's focus and the company's long-term strategy.
Why It Matters
Changes in executive compensation can signal shifts in company strategy or performance expectations, directly influencing how leadership is motivated and potentially impacting shareholder value.
Risk Assessment
Risk Level: medium — Changes in executive compensation can be a double-edged sword, potentially motivating performance or raising concerns about executive incentives.
Analyst Insight
Investors should monitor future filings or press releases from BioMarin Pharmaceutical Inc. for specific details regarding the changes to compensatory arrangements, as these details will clarify the potential impact on executive incentives and company strategy.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — the registrant filing the 8-K
- January 5, 2024 (date) — date of the earliest event reported
- January 11, 2024 (date) — date the 8-K was filed
- 000-26727 (other) — Commission File Number
- BMRN (other) — Trading Symbol for Common Stock
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 5, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 11, 2024.
What specific item number under Form 8-K does this filing address?
This filing addresses Item 5.02, which covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
What is the trading symbol for BioMarin Pharmaceutical Inc.'s common stock?
The trading symbol for BioMarin Pharmaceutical Inc.'s common stock is BMRN, and it is registered on The Nasdaq Global Select Market.
What is BioMarin Pharmaceutical Inc.'s business address?
BioMarin Pharmaceutical Inc.'s business address is 770 Lindaro Street, San Rafael, California, 94901.
Filing Stats: 463 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-01-11 16:06:52
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value BMRN The Nasdaq Global Se
Filing Documents
- d719423d8k.htm (8-K) — 23KB
- 0001193125-24-006599.txt ( ) — 137KB
- bmrn-20240105.xsd (EX-101.SCH) — 3KB
- bmrn-20240105_lab.xml (EX-101.LAB) — 17KB
- bmrn-20240105_pre.xml (EX-101.PRE) — 11KB
- d719423d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: January 11, 2024 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer